Pancreatic Cancer Research

ResearcherTongji HospitalNo recent work listed

Chengjian Shi

Matched on ORCID iD 0000-0003-1489-2022; OpenAlex author ID A5101748678. Sources: OpenAlex.

Their work

Papers
10 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
28
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: 1 paper · 2016: 3 papers · 2017: 1 paper · 2018: none · 2019: none · 2020: 1 paper · 2021: 2 papers · 2022: 1 paper

Papers 10

  1. OPA Interacting Protein 5 Antisense RNA 1 Expedites Cell Migration and Invasion Through FOXM1/ Wnt/β-Catenin Pathway in Pancreatic Cancer. Co-author DOI 10.1007/s10620-021-06919-1↗
  2. LncRNA RGMB-AS1 facilitates pancreatic cancer cell proliferation and migration but inhibits cell apoptosis via miR-574-3p/PIM3 axis. First author DOI 10.1152/ajpgi.00443.2020↗
  3. Inhibition of PI3K/AKT signaling via ROS regulation is involved in Rhein-induced apoptosis and enhancement of oxaliplatin sensitivity in pancreatic cancer cell… First author DOI 10.7150/ijbs.49514↗
  4. Upregulation of METTL14 mediates the elevation of PERP mRNA N6 adenosine methylation promoting the growth and metastasis of pancreatic cancer. Co-author DOI 10.1186/s12943-020-01249-8↗
  5. Inhibition of Autophagy by Deguelin Sensitizes Pancreatic Cancer Cells to Doxorubicin. Co-author DOI 10.3390/ijms18020370↗
  6. Par3 regulates invasion of pancreatic cancer cells via interaction with Tiam1. Co-author DOI 10.1007/s10238-015-0365-2↗
  7. Simultaneous inhibition of the ubiquitin-proteasome system and autophagy enhances apoptosis induced by ER stress aggravators in human pancreatic cancer cells. Co-author DOI 10.1080/15548627.2016.1191722↗
  8. Blocking NF-κB Is Essential for the Immunotherapeutic Effect of Recombinant IL18 in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-15-1144↗
  9. Synergistic antitumor activity of withaferin A combined with oxaliplatin triggers reactive oxygen species-mediated inactivation of the PI3K/AKT pathway in huma… Co-author DOI 10.1016/j.canlet.2014.11.026↗
  10. Pancreatic cancer cells resistant to chemoradiotherapy rich in "stem-cell-like" tumor cells. Co-author DOI 10.1007/s10620-010-1340-0↗

Closest collaborators

The 25 strongest of 28 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Renyi Qin · 8 shared papers, 2011–2022 · strength 0.58
  2. Min Wang · 6 shared papers, 2016–2022 · strength 0.50
  3. Li Xu · 3 shared papers, 2020–2022 · strength 0.36
  4. Ruizhi He · 4 shared papers, 2016–2021 · strength 0.29
  5. Wen-chong Song · 1 shared paper, 2021 · strength 0.28
  6. Xingjun Guo · 5 shared papers, 2015–2020 · strength 0.26
  7. Jianxin Jiang · 5 shared papers, 2015–2020 · strength 0.26
  8. Yan Zhao · 4 shared papers, 2016–2020 · strength 0.23
  9. Xiaodong Xu · 2 shared papers, 2016–2020 · strength 0.13
  10. Shutao Pan · 1 shared paper, 2021 · strength 0.12
  11. Xiuhui Shi · 1 shared paper, 2021 · strength 0.12
  12. Yuhui Liu · 1 shared paper, 2021 · strength 0.12
  13. Chunle Zhao · 1 shared paper, 2021 · strength 0.12
  14. Min Zhou · 1 shared paper, 2021 · strength 0.12
  15. Xu Li · 2 shared papers, 2016 · strength 0.09
  16. Jun Gong · 1 shared paper, 2020 · strength 0.08
  17. Shuo Yu · 1 shared paper, 2020 · strength 0.08
  18. Min Li · 1 shared paper, 2020 · strength 0.08
  19. Xiaohong Xu · 1 shared paper, 2017 · strength 0.06
  20. Renyi Qin · 1 shared paper, 2016 · strength 0.05
  21. Qing Zhong · 1 shared paper, 2016 · strength 0.05
  22. Chengyi Sun · 1 shared paper, 2016 · strength 0.05
  23. Xin Wang · 1 shared paper, 2015 · strength 0.04
  24. Chengyi Sun · 1 shared paper, 2015 · strength 0.04
  25. Xu Li · 1 shared paper, 2015 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.